(Q38108253)

29 August 2017

title

Stromal expression of SPARC in pancreatic adenocarcinoma (English)

1 reference

Annemilaï Tijeras-Raballand

29 August 2017

1 reference

2

object named as

Annemilaï Tijeras-Raballand

0 references

Cindy Neuzillet

1

object named as

Cindy Neuzillet

1 reference

29 August 2017

author name string

Annemilaï Tijeras-Raballand

2

1 reference

29 August 2017

Jérôme Cros

3

1 reference

29 August 2017

Sandrine Faivre

4

1 reference

29 August 2017

Pascal Hammel

5

1 reference

29 August 2017

Eric Raymond

6

1 reference

29 August 2017

publication date

1 December 2013

1 reference

Cancer and Metastasis Reviews

29 August 2017

published in

1 reference

29 August 2017

volume

32

1 reference

29 August 2017

issue

3-4

1 reference

29 August 2017

page(s)

585-602

1 reference

29 August 2017

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Pancreatic cancer: the role of pancreatic stellate cells in tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Stromal depletion goes on trial in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC in cancer biology: its role in cancer progression and potential for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Diverse biological functions of the SPARC family of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Molecular analysis of the cDNA for human SPARC/osteonectin/BM-40: sequence, expression, and localization of the gene to chromosome 5q31-q33

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Structural variability of BM-40/SPARC/osteonectin glycosylation: implications for collagen affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC (osteonectin/BM-40).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Modulation of matrix remodeling by SPARC in neoplastic progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Anti-cancer role of SPARC, an inhibitor of adipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

A peptide of SPARC interferes with the interaction between caspase8 and Bcl2 to resensitize chemoresistant tumors and enhance their regression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Mice deficient for the secreted glycoprotein SPARC/osteonectin/BM40 develop normally but show severe age-onset cataract formation and disruption of the lens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Osteopenia and decreased bone formation in osteonectin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC-null mice exhibit increased adiposity without significant differences in overall body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

The regulatory function of SPARC in vascular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Fibroblast growth factor receptor‐1 mediates the inhibition of endothelial cell proliferation and the promotion of skeletal myoblast differentiation by SPARC: A role for protein kinase A

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Regulation of the expression of a secreted acidic protein rich in cysteine (SPARC) in human fibroblasts by transforming growth factor beta. Comparison of transcriptional and post-transcriptional control with fibronectin and type I collagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC regulates the expression of collagen type I and transforming growth factor-beta1 in mesangial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC Inhibits Epithelial Cell Proliferation in Part through Stimulation of the Transforming Growth Factor-β–Signaling System

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC enhances tumor stroma formation and prevents fibroblast activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin beta1 and activation of integrin-linked kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Matricellular proteins and inflammatory cells: a task force to promote or defeat cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Matricellular proteins: a sticky affair with cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Frequent inactivation of SPARC by promoter hypermethylation in colon cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Aberrant promoter methylation of SPARC in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC ameliorates ovarian cancer-associated inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Normalization of the ovarian cancer microenvironment by SPARC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Delineation of prognostic biomarkers in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

The role of SPARC in the TRAMP model of prostate carcinogenesis and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Neuroblastoma angiogenesis is inhibited with a folded synthetic molecule corresponding to the epidermal growth factor-like module of the follistatin domain of SPARC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Venn Mapping: clustering of heterologous microarray data based on the number of co-occurring differentially expressed genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Stromal remodeling and SPARC (secreted protein acid rich in cysteine) expression in invasive ductal carcinomas of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Roles of osteonectin in the migration of breast cancer cells into bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC-induced increase in glioma matrix and decrease in vascularity are associated with reduced VEGF expression and secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

HSP27 mediates SPARC-induced changes in glioma morphology, migration, and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC modulates the proliferation of stromal but not melanoma cells unless endogenous SPARC expression is downregulated

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Osteonectin influences growth and invasion of pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC and DNA methylation: possible diagnostic and therapeutic implications in gastrointestinal cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-β1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Splenic and immune alterations of the Sparc-null mouse accompany a lack of immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Albumin-bound paclitaxel: a next-generation taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Role of taxanes in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

Osteopontin but not osteonectin favors the metastatic growth of pancreatic cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

A High-Throughput Study in Melanoma Identifies Epithelial-Mesenchymal Transition as a Major Determinant of Metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9439-3

10.1007/S10555-013-9439-3

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1002842037

0 references

1 reference